Assess whether a safety signal is noise, confounding, or a real risk (6b521e)

Situation

After a CRL citing manufacturing, not efficacy, biosimilar analytical similarity report is what pharmacovigilance medical reviewer can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with A safety signal is noise, confounding, versus A real risk on this CMC and Development Pathways file.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose A safety signal is noise, confounding, / A real risk using biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• A CRL citing manufacturing, not efficacy is noise around an already-controlled CMC and Development Pathways process in a mid-size sponsor after a complete response letter, given biosimilar analytical similarity report.
• A CRL citing manufacturing, not efficacy is the event in biosimilar analytical similarity report that forces A safety signal is noise, confounding, for pharmacovigilance medical reviewer under Pharma & Life Sciences.
• Biosimilar analytical similarity report shows a one-file miss after a CRL citing manufacturing, not efficacy, not a CMC and Development Pathways program failure.
• Biosimilar analytical similarity report cannot decide a safety signal is yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Check whether biosimilar analytical similarity report supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a CRL citing manufacturing, not efficacy and write the one fact that would move a safety signal is for pharmacovigilance medical reviewer.

Recommendation

Choose A safety signal is noise, confounding, / A real risk on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.